Ginkgo bioworks acquires bitome, an integrated metabolite monitoring platform

Through real-time metabolite monitoring, bitome's technology is expected to support accelerated product development timelines across ginkgo's portfolio of cell programs boston , june 6, 2022 /prnewswire/ -- ginkgo bioworks (nyse: dna), the leading horizontal platform for cell programming, today announced that it has acquired certain assets from bitome, a company pioneering real-time metabolite monitoring for faster biological product development. bitome has developed technology leveraging machine learning to provide continuous monitoring of cell culture media, illuminating the performance of cells in real-time and enabling faster rates of bioprocess optimization.
DNA Ratings Summary
DNA Quant Ranking